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INTRODUCTION 
SMEDDS is defined as isotropic mixture of lipid or oil, 
surfactant, co-surfactant and drug substance that rapidly 
form a fine oil-in-water microemulsionwhen exposed to 
aqueous media under condition of gentle agitation or 
digestive motility that would be encountered in the 
GIT.Self Emulsifying Drug Delivery Systems (SEDDS) 
andSMEDDS are the two types of self emulsifying 
systems
1
.Both SEDDS and SMEDDS have distinct 
features associated with improvement of drug delivery 
properties. SEDDS formulations are characterized by in 
vitro lipid droplet sizes of 200 nm to 5 mm and its 
dispersion has a turbid appearance
2, 3
. SMEDDS, however, 
have a smaller lipid droplet size (<100 nm) and its 
dispersion has an optically clear to translucent appearance. 
Both systems are associated with the generation of large 
surface area upon dispersions resulting into increased 
absorption of poorly soluble drugs
4, 5, 6
. 
Fexofenadine hydrochloride is an antihistaminic drug used 
in the treatment of hayfever and allergy symptoms. It is a 
third-generation antihistaminic agent. It does not readily 
pass through the blood-brain barrier, and hence causes less 
drowsiness than first-generation histamine-receptor 
antagonists. Fexofenadine hydrochloride has 33% 
absorption and 60-70 % protein binding. Half life of drug 
is 14.4 hours. Log P and pKa values of drug are 5.6 and 
13.2 respectively. Fexofenadine hydrochloride is poorly 
water soluble leading to lower absorption rate. Thus, there 
is a need to increase the solubility of drugto improve the 
absorption of drug via oral route. 
Present investigation was aimed to increase oral 
bioavailability of Fexofenadine hydrochloride. Self 
microemulsifying drug delivery system was developed to 
enhance oral solubility and in-vitro dissolution of drug. 
SMEDDS are physically stable formulations that are easy 
to manufacture. Thus, for lipophilic drugs these systems 
may offer an improvement in the rate and extent of 
absorption and results in more reproducible plasma level 
concentrations. 
MATERIALS AND METHODS 
Materials  
Fexofenadine hydrochloride was received as gift sample 
from Astron Research Centre, Ahmedabad, INDIA. 
ACONON MC8 was received as gift sample from 
ABITECH Corporation, INDIA. Aerosil200 was received 
as gift sample from Acron Pharmaceuticals, Ahmedabad, 
INDIA. Oleic acid, Polyethylene glycol 400 (PEG 400), 
Microcrystalline cellulose (MCC) was purchased from S. 
D. Fine Chemicals, Mumbai, INDIA. All other reagents 
used were of analytical grade. 
Experimental Methods 
Solubility studies  
Excess amount of Fexofenadine hydrochloride was added 
to 2 ml of each excipients were placed in test tubes and the 
mixture was vortexed and heated in a water bath to 
facilitate drug solubilization. The mixture was finally kept 
at ambient room temperature (25°C) under continuous 
shaking for 24 hours to attain equilibrium. Aliquots of 
supernatant were diluted with phosphate buffer (pH-6.8) 
and the drug content was measured at 220 nm using a UV 
spectrophotometer.
7,8,9
 Excipients used in solubility study 
were water, span 80, castor oil, oleic acid, polyethylene 
glycol 400, transcutol P,  acconon MC8, isopropyl alcohol 
(IPA), LabrafilM1944 Cs, tween 80, and cremophore 
RH40. 
Construction of Psuedoternary Phase Diagrams 
Self micro-emulsifying performance of Self 
Microemulsion (SME) mixture was assessed from their 
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ternary phase diagrams. Only the specific combinations of 
oil, surfactant and a co surfactant in the specific 
composition range were observed to produce a fine 
microemulsion upon aqueous dilution
10, 11
. To check 
emulsification efficiency of SME mixtures, test for 
emulsification was performed on all combinations and the 
resultant dispersions were visually assessed. The 
dispersions either formed a clear microemulsion, a slightly 
turbid emulsion or a milky emulsion which immediately 
was phase separated
12, 13, 14
. Nine combinations were 
prepared with the ratios of oil:(surfactant/co-surfactant) as 
1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7,1:8 and 1:9. The 
surfactant/co-surfactant ratios (Km) of 1:1, 1:2, 2:1 and 3:1 
were evaluated. Surfactant and co-surfactant mixtures 
possessing various Km ratios were prepared by weighing 
appropriate quantities of surfactant and co-surfactant and 
were vortexed for 30 min to produce a homogenous 
mixture.  
Mixtures with 12-50% of the oil, 25-66% of the surfactant 
and 12-44% of co-surfactant were evaluated for their self 
emulsifying properties. These mixtures were then mixed 
with the oil phase to form an isotropic SME mixture. Thus, 
each combination had a total of 9 samples with different 
proportions of oil, surfactants and co-surfactants.
15, 16 
Preparation of SMEDDS 
Liquid SMEDDS formulation was prepared by dissolving 
100 mg of Fexofenadine Hydrochloride in the optimized 
SMEDDS mixture consisting of oleic acid, Aconon MC8 
and PEG 400.Drug containing mixture was vortexed until 
a clear solution was obtained. These mixtures were 
observed for any signs of turbidity or phase separation for 
a period of 48 hours. Composition of Liquid SMEDDS for 
Fexofenadine Hydrochloride is shown in Table 1. 
Table 1: Composition of Fexofenadine SMEDDS 
Batch K
m  
ratio Drug 
(mg) 
Oil  
(%) 
Surfactant 
(%) 
Co-Surfactant (%) 
F1 1:1 100 25 37.5 37.5 
F2 1:2 100 20 26.3 53.3 
F3 2:1 100 16.6 55.5 27.7 
F4 3:1 100 50 37.5 12.5 
Drug: Fexofenadine hydrochloride 
Oil: Oleic acid 
Surfactant: Acconon MC 8  
co-surfactant: Polyethylene Glycol 400 
K
m  
ratio: Surfactant : co- surfactant ratio 
 
Preparation of Solid SMEDDS (S-SMEDDS) 
The optimized liquid SMEDDS formulation was converted 
into free flowing powder by adsorption of liquid SMEDDS 
onto solid carriers. The solid carriers used for adsorption 
comprised of materials that provided a high surface area 
with good disintegration characteristics
17, 18
. The solid 
carriers used include microcrystalline cellulose (MCC) and 
colloidal silicon dioxide (Aerosil 200). High levels of 
adsorption up to 95% (w/w) can be observed with the 
carriers chosen. The conversion process involved addition 
of liquid formulation on to carriers under continuous 
mixing in a blender. The optimized ratio for MCCand 
Aerosil 200 was 1:1 which was used for preparingS-
SMEDDS of all batches. The S-SMEDDS powder was 
used for further evaluation of parameters. The powder was 
dried and filled directly into capsules. 
Characterization of SMEDDS 
Test for Self Emulsification 
0.5 mL of sample mixture placed in 400 mL of water and 
contents were agitated with magnetic stirrer. The 
spontaneity of emulsification, clarity of dispersion, and 
apparent stability evaluated. The optimized formulation 
emulsified into a clear, transparent microemulsion and 
showed no signs of instability for 24 hours. 
Particle size of SMEDDS 
The Particle size of the resultant liquid SMEDDS was 
measured using Dynamic Light Scattering (Malvern Zeta 
analyzer Particle Sizing Systems). The liquid SMEDDS 
samples were taken in disposable glass tubes (VWR 
Scientific products) and particle size was determined. 
Drug Content  
10 mL petroleum ether was added to 1 mL of liquid 
SMEDDS containing Fexofenadine hydrochloride and 
mixed by shaking. The mixture was vortexed and 
centrifuged at 1000 rpm for 3minutes.Finally, the upper 
liquid phase was collected and assayed 
spectrophotometrically for the drug content at the 
wavelength 220nm with proper dilution of petroleum ether 
as blank. 
In-vitro drug release studies of SMEDDS 
In-vitro drug release studies from liquid SMEDDS were 
performed using USP Type I dissolution apparatus (basket 
apparatus) at 100 rpm. Liquid SMEDDS preparation 
equivalent to 100mg Fexofenadine Hydrochloride was 
filled into soft gelatin capsule. The dissolution medium 
consisted of 900 ml of phosphate buffer pH 6.8 maintained 
at 37 ±0.5°C. At predetermined time intervals 5ml of 
aliquot was withdrawn, and an equivalent volume of fresh 
dissolution medium was immediately added. The amount 
of drug released was estimated by measuring absorbance at 
220 nm using a spectrophotometer. 
Angle of repose 
A funnel was kept vertically in stand at a specified height 
above a paper placed on horizontal surface. The bottom 
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was closed and 10 gm of sample powder was filled in 
funnel. The funnel was opened to release the powder on 
paper to form a smooth conical heap. The height of heap 
was measured using the scale. A border of heap was 
marked circularly and its diameter was measured at four 
points. The average diameter was calculated and radius 
was found out from it. The angle of repose was calculated 
using following formula: 
tan θ     ------------------- (2) 
Where; h = height of the heap, r = radius of the heap 
In-vitro Drug Release Studies From S-SMEDDS 
In vitro drug release studies from S-SMEDDS were 
performed using USP Type I dissolution apparatus 
(dissolution tester) with number of basket rotations set to 
50 rpm. The dissolution medium consisted of 900 mL of 
phosphate buffer pH 6.8 maintained at 37 ±0.5°C. S-
SMEDDS containing 100 mg of Fexofenadine 
Hydrochloride was introduced into a gelatin capsule shell 
and was put into the dissolution medium. At predetermined 
time intervals 5 mL of aliquot was withdrawn and an 
equivalent volume of fresh dissolution medium was 
immediately added. The amount of drug released was 
estimated by measuring absorbance at 220 nm using a 
Double beam spectrophotometer (Shimanzdu UV 1800 
spectrophotometer). Dissolution of liquid SMEDDS and 
marketed preparation was also determined in identical 
manner. The calibration curve of drug was made in 
phosphate buffer pH 6.8 and at 220 nm. 
RESULTS AND DISCUSSION 
Solubility studies 
Solubility study of drug in different oils, surfactant, co-
surfactant was shown in Table 2. According to that 
Fexofenadine hydrochloride showed higher solubility in 
oleic acid, acconon MC8 and PEG 400. Solubility of drug 
in oleic acid was found 6.38 ± 005 mg/mL. Solubility of 
drug in Acconon MC8 was found 22.48 ± 0.38 mg/mL. 
Table 2: Solubility of Fexofenadine Hydrochloride in 
various Solvents 
Solvents Solubility (mg/mL ) ±  SD 
Water 1.62 ± 0.05 
Span 80 11.56 ± 0.04 
Castor Oil 0.38 ± 0.02 
Oleic Acid 6.38 ± 0.05 
PEG 400 17.12 ± 0.4 
Transcutol P 15.13 ± 0.5 
Acconon MC8 22.46 ± 0.38 
IPA 20.57 ± 0.26 
Labrafil M1944 Cs 0.24 ± 0.05 
Tween 80 13.27 ± 0.14 
Cremophore RH40 9.67 ± 0.27 
Ternary Phase diagrams 
Solubility of drug in mixture of oleic acid, Acconon MC8 
and PEG 400 were selected for construction of 
pseudoternary phase diagrams. Total nine combinations 
were prepared. Phase diagrams for various ratios of 
surfactant and co-surfactant (1:1, 1:2, 2:1, 3:1) were 
constructed.
19
 The phase diagrams for surfactant- co-
surfactant ratio 1:1, 1:2, 2:1, 3:1 were shown in Figure 1, 
2, 3 and 4 respectively. Phase diagrams for Km ratio 1:1 
and 1:2 was quite similar while phase diagrams for Km 
Ratio 2:1 and 3:1 were similar. 
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From the results of self emulsification time, droplet size and visual inspection of all the combination of Km ratio 1:1, 1:2, 
2:1 and 3:1, four batches were selected as best formulation for preparation of liquid SMEDDS. Ratio of oleic Acid, 
Acconon MC8 and PEG 400 for Km ratio 1:1, 1:2, 2:1 and 3:1 were presented in Table 3. All four combinations were also 
evaluated for particle size, self emulsification time and visual Inspection. 
Self microemulsifying performance of SME mixture was assessed from their ternary phase diagrams and time taken to 
produce a fine microemulsion. To check emulsification efficiency of SME mixtures, test for emulsification was performed 
on all combinations and the resultant dispersions were visually assessed. Resulting dispersions either formed a clear 
microemulsion, a slightly turbid emulsion or a milky emulsion which immediately phase separate.
20, 21, 22, 23
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Table 3: Composition of Liquid SMEDDS 
Batch Km  ratio Drug(mg) Oil (%) Surfactant(%) Co-Surfactant (%) 
F1 1:1 100 25 37.5 37.5 
F2 1:2 100 20 26.3 53.3 
F3 2:1 100 16.6 55.5 27.7 
F4 3:1 100 50 37.5 12.5 
 
Characterization of Liquid SMEDDS 
Test for Self Emulsification 
The SMEDDS formed either a visually clear 
microemulsion, or a slightly turbid emulsion, or a milky 
emulsion that immediately phase separated. The optimized 
formulation emulsified into a clear, transparent 
microemulsion and showed no signs of instability for 24 
hours. Results of self-emulsification time were shown in 
Table 4. 
Table 4:  Self Emulsification Time of Batches F1-F4 
Batch Km  ratio Self Emulsification Time (Second) Visual Observation 
F1 1:1 45 Good 
F2 1:2 42 Good 
F3 2:1 62 Good 
F4 3:1 56 Good 
 
Particle size analysis 
The Particle size of the liquid SMEDDS is important since 
it determines the rate and extent of drug release and 
absorption. The drug can diffuse faster from smaller 
droplets into the aqueous phase, thereby increasing the 
drug dissolution. Smaller droplet size presents large 
surface area for drug absorption.
24
 Increase in surfactant 
concentration decreases the droplet size up to a certain 
level but thereafter anyfurther increase results in an 
increase in droplet size. The reduction in droplet size can 
be attributed to the stabilization of oil droplets due to 
localization of surfactant monolayers at the oil-water 
interface.
25
 Increase in surfactant concentration causes 
enhanced water penetration into oil droplets leading to 
breakdown of oil droplets and resultant bigger droplets. 
The droplet size of the nanoemulsion was measured using 
dynamic light scattering. The loaded SMEDDS displayed a 
Gaussian distribution of droplet sizes.
26, 27, 28
Theparticle 
size of the resultant Liquid SMEDDS was measured using 
Dynamic Light Scattering (Malvern Zeta Analyser Particle 
Sizing Analyser). Results of particle size analysis as 
presented in Table 5. Particle size of batch F1 and F4 were 
found to be 117.3 nm and 166 nm respectively. Batch F2 
and F3 showed lower particle size 57.30 nm and 61.21 nm. 
Table 5: Average particle size of liquid SMEDDS 
Batch Km  ratio Size(nm) % Intensity Width(nm) 
F1 1:1 117.3 100 20.56 
F2 1:2 57.30 97.4 7.14 
F3 2:1 61.21 88.5 10.47 
F4 3:1 166 100 26.14 
Km   ratio: Surfactant- co-surfactant ratio 
 
Drug Content 
All the batches F1-F4 were assayed spectrophotometrically 
for the drug content at the wavelength 220 nm with proper 
dilution of formulations taking phosphate buffer (PH-6.8) 
as blank
29, 30
. Results of content uniformity were shown in 
Table 6. It showed all the batches have a minimum of 98% 
content uniformity. Among all the batches F2 had highest 
content uniformity 99.12%. 
Table 6: % Drug Content 
Batch % Drug Content±SD 
F1 98.45 ± 0.04 
F2 99.12 ± 0.24 
F3 97.38 ± 0.08 
F4 98.52 ± 0.17 
 
 
Drug release studies of SMEDDS 
The in vitro dissolution of the Liquid SMEDDS 
Formulation F1-F4 was performed in phosphate buffer of 
pH 6.8 using a USP Type I dissolution apparatus with a 
basket speed of 100 RPM. Liquid SMEDDS dissolution 
medium and were sampled at regular intervals until 
complete drug release was observed. The amount of drug 
released was calculated from the calibration curve of 
Fexofenadine Hydrochloride. In vitro dissolution curve of 
batches F1 to F4 were shown in Figure 5. According to 
results batch F3 and F4 were found to have complete drug 
release in 140 min and 180 min respectively. Both F1 and 
F2 showed complete drug release in 70 and 80 min. Higher 
dissolution rate of batch F1 and F2 was observed due to 
lower globule size of liquid SMEDDS. From the of in-
vitro drug release data, content uniformity and particle size 
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batch F2 was selected as optimized batch for pre-
formulation of solid SMEDDS. 
 
Angle of Repose 
Angle of Repose of all four Batch F1-F4 was found with 
having good flow properties. Batch F1, F2, F3 and F4 
having angle of repose 24.17 ± 0.017, 26.32 ± 0.24, 28.56 
± 0.053, 24.83 ± 0.64 respectively. 
In vitro drug release studies From Solid SMEDDS 
The in-vitro dissolution of the Solid SMEDDS 
Formulation F1 to F4 was performed in phosphate buffer 
of pH 6.8 using a USP Type I dissolution apparatus with a 
basket speed of 100 RPM. Solid SMEDDS dissolution 
medium and were sampled at regular time intervals until 
complete drug release was observed. The amount of drug 
released was calculated from the calibration curve of 
Fexofenadine Hydrochloride. Figure 6 showed in-vitro 
dissolution curve of solid SMEDDS. According to that 
almost complete drug release was observed within 90 min 
which was compared with marketed product and liquid 
SMEDDS. 
 
CONCLUSION 
A particular SME mixture comprising of oleic acid, 
Aconon MC8 and PEG 400 was selected and optimized for 
the purpose for delivering Fexofenadine hydrochloride. 
Four different formulations of different Km ratio were 
prepared. Among this four prepared formulations of Liquid 
SMEDDS, formulation F2 containing 20% oil, 26.3% 
surfactant and 53.3% co-surfactant was selected as 
optimized formulation. Optimized formulation had 
57.30µm particle size and complete drug release in 90 
minutes.In conclusion, Self emulsifying drug delivery 
systems were a promising approach for the formulation of 
Fexofenadine Hydrochloride. The oral delivery of 
hydrophobic drugs can be made possible by SMEDDSs, 
which have been shown to substantially improve oral 
bioavailability.  
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